Sept. 8, 2008 - Personal Continuous Glucose Monitoring Further Validated by Independent Study – Results of the largest ever Continuous Glucose Monitoring (CGM) study were published online by the New England Journal of Medicine. The study demonstrated that Personal CGM therapy significantly reduced the average blood glucose levels (A1c) of adult patients with type 1 diabetes, validating the growing body of clinical evidence in support of Personal CGM therapy and its ability to substantially improve diabetes management and glucose control. Studies have shown that reducing A1c can result in reduced risk of long-term side effects associated with diabetes, including blindness and kidney disease.The multicenter, 322-patient trial, funded by the Juvenile Diabetes Research Foundation (JDRF), found that after six months adults using Personal CGM realized a statistically significant 0.53 percent absolute reduction in A1c as compared to the control group. All patients in the study experienced statistically significant absolute reductions in A1c levels ranging from 0.5 to 0.7 percent when Personal CGM was used at least six days a week. Moreover, improvements in A1c occurred without an increase in severe hypoglycemia (low blood sugar)... Medtronic's Press Release -
